Apply for a licence to market a medicine in the UK

An overview of the process including submitting or fast tracking an application, naming your medicine and paying fees.

This information is common to all procedures. You should read the guidance for your specific pathway for any extra information or steps that might be required. The pathway that you follow will depend on your intended market and the type of application you are making.

Find out more about the different national and international procedures

Application process

All UK and Great Britain (England, Scotland and Wales) national applications should be submitted through the MHRA Submissions Portal.

If you have any questions about the Submissions Portal, you should email

You should submit your application using the electronic Common Technical Document (eCTD).

Use the pre-submission checklist (PDF, 129 KB, 7 pages) to help you with your application. You should also use our eAF and cover letter tool to determine what information you need to include in your application. If you do not include the correct information your application will not be validated.

We recommend that you use a validation tool to check your submission as we will check that NeeS and eCTD submissions are technically valid using the Extedo Eurs is Yours (EiY) validation tool.

If you have any questions about submitting your application you should email

PL number

If you are applying for a UK, Great Britain or Northern Ireland licence, you must get a PL number from MHRA Submissions or by emailing before you submit your application.

Please note the following prefixes and their definitions:

  • PL: a product licensed by the MHRA that covers the whole of the UK, coming into effect from 1 January 2025. Please see more information in the following guidance: UK-wide licensing for human medicines - GOV.UK
  • PLNI: a product licensed by the MHRA that covers Northern Ireland (NI) only as the territorial application.
  • PLGB: a product licensed by the MHRA that covers Great Britain (GB) only as the territorial application

Active substance master files (ASMFs)

ASMFs holders must submit their dossier to the MHRA. It is the MA applicant’s responsibility to make sure that the ASMF is submitted either before you submit your application or at the same time, as your application will not be valid without it.

Submission of a new ASMF and any update to an ASMF should be made by the ASMF holder using MHRA Submissions . If you have any questions about MHRA Submissions , you should email

You can read our guidance about the submission of ASMFs.

Certificates of Suitability (CEPs) continue to be acceptable in support of UK and GB national authorisations.

Summary of product characteristics (SmPC)

The summary of product characteristics (SmPC) should be submitted to the MHRA in the correct format using the SPC template (MS Word Document, 36 KB). If you do not use this template your submission will be rejected. These templates should not be altered in any way, other than inserting the relevant information.

Established medicines

For established active substance marketing authorisation applications (MAAs).

Process for review

New process change guidance from 1 March 2024 to ensure applications are complete on initial assessment, or as soon after submission as possible.

Read more about the Established Medicines licensing process changes

Watch the video of the Established Medicines licensing process changes webinar

Checklists - established active substance MAAs

For established active substances within scope of the relevant checklist, applicants are encouraged to submit the following documents with the initial submissions. The main purpose of these checklists is to promote ‘right first time’ submissions.

UK Public Assessment Report (UKPAR) templates

The lay summary of the UK PAR forms are completed by the Applicant of a National Abridged applications only following the Request for Further Information (RFI) from the MHRA.

Providing a name for your medicine

MHRA considers each application for a product name to ensure that the proposed name will allow the medicine to be taken safely and correctly.

You can find out more in our naming of medicines guidance (PDF, 235 KB, 20 pages).

Fast track your marketing authorisation

Applications can be fast tracked if there is compelling evidence of benefit in a public health emergency or if there is a shortage of supply of an essential medicine that has been verified by the Department of Health and Social Care (DHSC).

To make a request for fast tracking your marketing authorisation you should email a letter of no more than 3 pages to

The letter should include:

  • the justification for fast tracking
  • a brief description of the major clinical properties of the product
  • evidence supporting the claimed benefits of the product for the proposed indication(s)

If you want to fast track your application because of a shortage of supply we recommend you discuss this with DHSC by emailing

There is no additional fee for fast-tracking applications.


Fees vary depending on the type and route of application. You can find out more about the fees we charge in the guidance MHRA fees.

Use the Fees Calculator to work out what the fee for your submission will be.

You can find out more about how to pay your fees in our guidance on making a payment to MHRA.

Purchase Orders (POs)

It is your responsibility to make sure the invoices for your submissions are paid on time. If your organisation operates a PO system, please make sure that the relevant PO is provided to the MHRA before the invoice is issued.

Refusal to pay outstanding fees on the grounds that the PO is not provided on the invoice will not be accepted. The use of POs is an internal control process and cannot be used as a reason to withhold payment of legitimate invoices.


Once your application has been validated you will receive an invoice so that you can make a payment for the outstanding amount. All invoices must be settled upon receipt.

Penalty fees may be incurred for non-payment. Details of the penalties are explained in our Fees Regulations.

Non-payment may also result in suspension of any licence or authorisation, followed by legal proceedings for any unpaid amounts, as a debt due to the Crown.


Any submission that does not meet the requirements will be rejected.

If a submission is rejected, we will email you the reasons for the rejection. You must then resend the entire submission with the errors corrected. Do not send the corrected deficiencies by email.

You will not be charged if your submission is rejected for technical reasons.

If you think your submission has been wrongly rejected, you should email

Published 18 December 2014
Last updated 14 March 2024 + show all updates
  1. Edited to add Youtube tutorial for Established Medicines licensing process

  2. Details about new process changes which are being introduced for applications for  “Established Medicines”.

  3. Updated to add further guidance on obtaining a PL number for applications

  4. Added link to Fees Calculator.

  5. Added 'Checklist and abstract for bioequivalence studies and/or biowaivers' and 'Checklist for product information', for established active substance MAAs within scope.

  6. Added links to pages providing further information on some of the procedures.

  7. Following the end of the transition period, published information on new procedures for obtaining a marketing authorisation in the UK, Great Britain (England, Scotland and Wales) or Northern Ireland.

  8. Updated content to reflect that the UK cannot act as a Reference Members State (RMS) for approval of marketing authorisations in decentralised and mutual recognition licensing procedures during the transition period.

  9. The DHSC contact for fast-tracking a licence has changed.

  10. Inserted text - Request for Information (RFI)... Under 'Ways to make your submission'

  11. Updated email address and naming to Department of Health and Social Care

  12. Removed link to Excel spreadsheet list of products.

  13. Added spreadsheet under "types of application" heading

  14. Added a link to the User Guide for the electronic application form.

  15. Updated contact information for Department of Health for advice when seeking to fast-track an application due to a shortage of supply of essential medicines.

  16. New fees calculator.

  17. First published.